Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Change of pitch due to carbamazepine and oxcarbazepine independently.

Gur-Ozmen S, Nirmalananthan N, von Oertzen TJ.

Seizure. 2013 Mar;22(2):162-3. doi: 10.1016/j.seizure.2012.11.010. Epub 2012 Dec 21. No abstract available.

2.

Reversible pitch perception deficit due to carbamazepine.

Kashihara K, Imai K, Shiro Y, Shohmori T.

Intern Med. 1998 Sep;37(9):774-5. Review.

3.

Oxcarbazepine approved for partial seizures.

Miller JL.

Am J Health Syst Pharm. 2000 Mar 1;57(5):414, 417. No abstract available.

PMID:
10711517
4.

Oxcarbazepine for epilepsy--a useful new choice?

[No authors listed]

Drug Ther Bull. 2002 Jun;40(6):46-8. Review.

PMID:
12143266
5.

Oxcarbazepine: new preparation. An alternative to carbamazepine in partial epilepsy.

[No authors listed]

Prescrire Int. 2001 Dec;10(56):170-4.

PMID:
11824439
6.

[Oxcarbazepine-induced localized penile edema].

Rallis E, Theodoridis A, Moussatou V, Papadakis P, Verros C.

J Dtsch Dermatol Ges. 2005 Oct;3(10):786-7. German.

PMID:
16194158
7.

Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures.

Koch MW, Polman SK.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453. doi: 10.1002/14651858.CD006453.pub2. Review.

PMID:
19821367
8.

Seizure exacerbation associated with oxcarbazepine in idiopathic focal epilepsy of childhood.

Chapman K, Holland K, Erenberg G.

Neurology. 2003 Oct 14;61(7):1012-3. No abstract available.

PMID:
14557585
9.

[Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis].

Homberg V, Kowalik A, Schulze-Bonhage A.

Nervenarzt. 2001 Dec;72(12):918-23. German.

PMID:
11789435
10.

Pitch perception shift: a rare side-effect of carbamazepine.

Kobayashi T, Nisijima K, Ehara Y, Otsuka K, Kato S.

Psychiatry Clin Neurosci. 2001 Aug;55(4):415-7. Review.

11.

Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.

Lee SA, Heo K, Kim WJ, Song HK, Kim SE, Kim SH, No SK, Lee BI.

Seizure. 2010 Jul;19(6):356-8. doi: 10.1016/j.seizure.2010.05.002. Epub 2010 Jun 9.

12.

Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.

Kruszewski SP, Klotz SG.

Neurology. 2007 Feb 6;68(6):472; author reply 472-3. No abstract available.

PMID:
17283329
13.

[Experience with eslicarbazepine in patients with hiponatremia due to carbamazepine and oxcarbacepine].

Bermejo PE, Dorado R, Belarrinaga B.

Rev Neurol. 2015 Jul 1;61(1):47-8. Spanish.

14.

The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures.

Donati F, Gobbi G, Campistol J, Rapatz G, Daehler M, Sturm Y, Aldenkamp AP; Oxcarbazepine Cognitive Study Group.

Seizure. 2007 Dec;16(8):670-9. Epub 2007 Jun 18.

15.

Hyponatremia induced by oxcarbazepine.

Johannessen AC, Nielsen OA.

Epilepsy Res. 1987 Mar;1(2):155-6.

PMID:
3143548
16.

Carbamazepine-induced abnormal pitch perception.

Yoshikawa H, Abe T.

Brain Dev. 2003 Mar;25(2):127-9.

PMID:
12581810
17.

Oxcarbazepine-induced leukopenia.

Milia A, Pilia G, Mascia MG, Moller J, Cocco E, Marrosu MG.

J Neuropsychiatry Clin Neurosci. 2008 Fall;20(4):502-3. doi: 10.1176/appi.neuropsych.20.4.502. No abstract available.

PMID:
19196947
18.

Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial.

Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG.

Lancet Neurol. 2012 Apr;11(4):331-40. doi: 10.1016/S1474-4422(12)70018-2. Epub 2012 Feb 28.

19.

Reversible pitch perception deficit caused by carbamazepine.

Miyaoka T, Seno H, Itoga M, Horiguchi J.

Clin Neuropharmacol. 2000 Jul-Aug;23(4):219-21.

PMID:
11020128
20.

Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience.

Kothare SV, Khurana DS, Mostofi N, Melvin JJ, Marks HG, Valencia I, Legido A.

Pediatr Neurol. 2006 Oct;35(4):235-9.

PMID:
16996394
Items per page

Supplemental Content

Write to the Help Desk